At the genomic level, we first observed that breast tumors expressing low FBL mRNA levels had significantly lower number of copy alterations or mutation counts than breast tumors exhibiting high FBL mRNA levels, supporting that the two FBL-related tumor groups are different (Supplementary figure S5A-B). This evidence concerns the gene FBL and neoplasm.